Table 1.
Baseline demographic data of endoscopic and nephroureterectomy (RNU) managed UTUC.
| Variables | Endoscopic | RNU | p-valuea | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Gender | |||||
| Men | 36 | (42.90) | 118 | (43.40) | 0.932 |
| Women | 48 | (57.10) | 154 | (56.60) | |
| Ageb mean ± SD | 68.8 ± 11.5 | 67.6 ± 10.6 | 0.331 | ||
| BMIb mean ± SD | 23.7 ± 3.8 | 24.1 ± 3.8 | 0.431 | ||
| Hospital stay (day)b median | 2.0 | 8.0 | < 0.001** | ||
| Follow up (months)b median | 33.5 | 42.0 | 0.082 | ||
| ECOG | |||||
| Normal activity fully ambulatory | 64 | (76.19) | 125 | (45.96) | 0.002** |
| Symptoms, but nearly fully ambulatory | 17 | (20.24) | 101 | (37.13) | |
| Some bed time, but needs to be in bed less than 50% of normal daytime | 3 | (3.57) | 10 | (3.68) | |
| Needs to be in bed more than 50% of normal daytime | 0 | (0.00) | 1 | (0.37) | |
| Risk factor | |||||
| Smoking | 4 | (4.76) | 51 | (18.75) | 0.016* |
| Chemical exposure | 0 | (0.00) | 14 | (5.15) | 0.068 |
| Herbal supplements | 3 | (3.57) | 32 | (11.76) | 0.106 |
| Arsenic water | 1 | (1.19) | 17 | (6.25) | 0.145 |
| ESRD/CRI | 18 | (21.43) | 60 | (22.06) | 0.193 |
| Previous nephroureterectomy for UC | 18 | (21.43) | 7 | (2.57) | < 0.001** |
| Regular hair coloring | 2 | (2.38) | 25 | (4.75) | 0.119 |
| Comorbidity | |||||
| CAD | 8 | (9.52) | 31 | (11.40) | 0.604 |
| Arrythmi | 4 | (4.76) | 10 | (3.68) | 0.672 |
| HTN | 49 | (58.33) | 134 | (49.26) | 0.177 |
| ESRD | 4 | (4.76) | 39 | (14.34) | 0.017* |
| DM | 23 | (27.38) | 70 | (25.74) | 0.816 |
| Gout | 9 | (10.71) | 12 | (4.41) | 0.035* |
| GI | 9 | (10.71) | 33 | (12.13) | 0.693 |
| Malignancy (No UTUC/bladder UC) | 7 | (8.33) | 30 | (11.03) | 0.457 |
| Tumor location | |||||
| Renal pelvis | 73 | (86.90) | 172 | (63.24) | < 0.001** |
| Ureter | 22 | (26.19) | 141 | (51.84) | < 0.001** |
| Tumor size (cm) | |||||
| < 2 | 74 | (88.10) | 102 | (37.50) | < 0.001** |
| ≥ 2 | 7 | (8.33) | 163 | (59.93) | |
| Affected kidney at diagnosis | |||||
| Left | 41 | (48.81) | 123 | (45.22) | 0.253 |
| Right | 40 | (47.62) | 144 | (52.94) | |
| Bilateral | 2 | (2.38) | 4 | (1.47) | |
| Multifocality | |||||
| Not available | 2 | (2.38) | 1 | (0.37) | < 0.001** |
| No | 16 | (19.05) | 191 | (70.22) | |
| Yes | 62 | (73.81) | 77 | (28.31) | |
| Pre-op urine cytology | |||||
| Negative | 18 | (21.4) | 36 | (13.2) | 0.658 |
| Atypia | 18 | (21.4) | 48 | (17.6) | |
| Positive | 33 | (39.3) | 90 | (33.1) | |
| Synchronous bladder urothelial cancer | |||||
| Previous Hx of bladder UC | 20 | (23.81) | 29 | (10.66) | 0.001** |
| Concurrent bladder UC | 7 | (8.33) | 41 | (15.07) | |
| Preoperative hydronephrosis | 47 | (55.95) | 155 | (56.99) | 0.767 |
| Bladder UC after RNU/endoscopic ablation | 19 | (22.62) | 91 | (33.46) | 0.481 |
| Definitive chemotherapy for advanced/metastasis UTUC | 7 | (8.33) | 41 | (15.07) | 0.178 |
| Radiation therapy for UTUC | 2 | (2.38) | 14 | (5.15) | 0.251 |
| Biopsy tumor grading | |||||
| Benign lesion | 0 | (0.00) | 5 | (1.84) | 0.317 |
| Papillary urothelial neoplasm of low malignant potential | 0 | (0.00) | 4 | (1.47) | |
| Low grade | 28 | (33.33) | 60 | (22.06) | |
| High grade | 43 | (51.19) | 84 | (30.88) | |
| G2 (WHO 1973) | 0 | (0.00) | 5 | (1.84) | |
| Dysplasia/atypia | 2 | (2.38) | 6 | (2.21) | |
| Biopsy failure | 3 | (3.57) | 8 | (2.94) | |
| Clinical T stage T | |||||
| cTx | 72 | (85.71) | 196 | (72.06) | 0.008** |
| cTa | 7 | (8.33) | 15 | (5.51) | |
| cT1 | 3 | (3.57) | 41 | (15.07) | |
| cT2 | 2 | (2.38) | 20 | (7.35) | |
aChi-Squared test calculated for the difference Variables.
bStudent’s t-test calculated for the difference in means.
*< 0.05.
**< 0.01.